Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus

Stefan Beissert*, Thomas Werfel, Uta Frieling, Markus Böhm, Michael Sticherling, Rudolf Stadler, Detlev Zillikens, Berthold Rzany, Nicolas Hunzelmann, Michael Meurer, Harald Gollnick, Thomas Ruzicka, Hans Pillekamp, Volker Junghans, Thomas Luger

*Korrespondierende/r Autor/-in für diese Arbeit

Abstract

Objective: To investigate the safety and efficacy of oral methylprednisolone combined with azathioprine sodium or mycophenolate mofetil for the treatment of pemphigus. Design: A prospective, multicenter, randomized, non-blinded clinical trial to compare 2 parallel groups of patients with pemphigus (pemphigus vulgaris and pemphigus foliaceus) treated with oral methylprednisolone plus azathioprine or oral methylprednisolone plus mycophenolate mofetil. Settings: Thirteen departments of dermatology in Germany. Patients: We included patients with pemphigus vulgaris (n=33) or pemphigus foliaceus (n=7) evidenced by clinical lesions suggestive of pemphigus, intraepidermal blistering on histological analysis of skin biopsy specimens, intercellular deposition of IgG within the epidermis, and immunoblot analysis findings for antidesmoglein 3 and/or antidesmoglein 1 autoantibodies. Main Outcome Measures: The cumulative total methylprednisolone doses and rate of remission. Secondary outcome measures were safety profiles and duration of remission. Results: In 13 (72%) of 18 patients with pemphigus receiving oral methylprednisolone and azathioprine, complete remission was achieved after a mean±SD of 74±127 days compared with 20 (95%) of 21 patients receiving oral methylprednisolone and mycophenolate mofetil in whom complete remission occurred after a mean±SD of 91±113 days. The total median cumulative methylprednisolone dose used was 8916 mg (SD, ±29 844 mg) in the azathioprine group compared with 9334 mg (SD, ±13 280 mg) in the mycophenolate group. In 6 (33%) of 18 patients treated with azathioprine, grade 3 or 4 adverse effects were documented in contrast to 4 (19%) of 21 patients who received mycophenolate mofetil. Conclusion: Mycophenolate mofetil and azathioprine demonstrate similar efficacy, corticosteroid-sparing effects, and safety profiles as adjuvants during treatment of pemphigus vulgaris and pemphigus foliaceus.

OriginalspracheEnglisch
ZeitschriftArchives of Dermatology
Jahrgang142
Ausgabenummer11
Seiten (von - bis)1447-1454
Seitenumfang8
ISSN0003-987X
DOIs
PublikationsstatusVeröffentlicht - 2006

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

  1. SDG 3 – Gesundheit und Wohlergehen
    SDG 3 – Gesundheit und Wohlergehen

Fingerprint

Untersuchen Sie die Forschungsthemen von „A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren